1% Azithromycin and 0.1% Dexamethasone + 1% Azithromycin + 0.1% Dexamethasone
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Blepharoconjunctivitis
Conditions
Blepharoconjunctivitis
Trial Timeline
Dec 1, 2007 → Oct 1, 2008
NCT ID
NCT00578955About 1% Azithromycin and 0.1% Dexamethasone + 1% Azithromycin + 0.1% Dexamethasone
1% Azithromycin and 0.1% Dexamethasone + 1% Azithromycin + 0.1% Dexamethasone is a phase 3 stage product being developed by Sun Pharmaceutical for Blepharoconjunctivitis. The current trial status is completed. This product is registered under clinical trial identifier NCT00578955. Target conditions include Blepharoconjunctivitis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00754949 | Phase 3 | Withdrawn |
| NCT00578955 | Phase 3 | Completed |
Competing Products
2 competing products in Blepharoconjunctivitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| 1% Azithromycin and 0.1% Dexamethasone + 1% Azithromycin + 0.1% Dexamethasone | Sun Pharmaceutical | Phase 3 | 77 |
| Azithromycin ophthalmic solution, 1% | Merck | Phase 2 | 52 |
Other Products from Sun Pharmaceutical
Ilumya Injectable ProductApproved
85
CequaTM (Cyclosporine 0.09%) ophthalmic solutionApproved
85
Cyclosporine + Artificial tearApproved
85
AmifostineApproved
85
Ilaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapy + Esoprazole antisecretory drug of each quadruple therapy Esoprazole-based quadruple therapyApproved
85